This is supported by evidence showing that inhibiting AKT or mTOR, either pharmacologically or genetically, fails to suppress cell growth or induce cell cycle arrest, even in the presence of elevated pAKT levels across melanoma cell lines. Here, MTOR is linked to melanoma.